Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Latest concepts in frontline therapy for paediatric ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )
19 Dec 2019

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
19 Dec 2019

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain
The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )
19 Dec 2019

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019